Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The phytoalexin camalexin mediates cytotoxicity towards aggressive prostate cancer cells via reactive oxygen species.

Smith BA, Neal CL, Chetram M, Vo B, Mezencev R, Hinton C, Odero-Marah VA.

J Nat Med. 2013 Jul;67(3):607-18. doi: 10.1007/s11418-012-0722-3. Epub 2012 Nov 24.

2.

Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells.

Neal CL, Henderson V, Smith BN, McKeithen D, Graham T, Vo BT, Odero-Marah VA.

BMC Cancer. 2012 Aug 2;12:336. doi: 10.1186/1471-2407-12-336.

3.

Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit.

Neal CL, Xu J, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL, Yu D.

Oncogene. 2012 Feb 16;31(7):897-906. doi: 10.1038/onc.2011.284. Epub 2011 Jul 11.

4.
5.

14-3-3ζ as a prognostic marker and therapeutic target for cancer.

Neal CL, Yu D.

Expert Opin Ther Targets. 2010 Dec;14(12):1343-54. doi: 10.1517/14728222.2010.531011. Review.

6.

Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.

Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D.

Cancer Res. 2009 Dec 15;69(24):9163-8. doi: 10.1158/0008-5472.CAN-09-2483.

7.

ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D.

Mol Cancer Res. 2009 Apr;7(4):592-600. doi: 10.1158/1541-7786.MCR-08-0316.

8.

14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.

Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D.

Cancer Res. 2009 Apr 15;69(8):3425-32. doi: 10.1158/0008-5472.CAN-08-2765. Epub 2009 Mar 24.

9.

14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling.

Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D.

Cancer Res. 2008 Mar 15;68(6):1760-7. doi: 10.1158/0008-5472.CAN-07-3177.

10.

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D.

Clin Cancer Res. 2007 Oct 1;13(19):5883-8.

12.

Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.

Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L, Porter PL.

Cancer Res. 2004 Dec 1;64(23):8541-9.

13.

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.

Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D.

Mol Cell. 2002 May;9(5):993-1004.

14.

Altered transcription in yeast expressing expanded polyglutamine.

Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, Fields S.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13201-6. Epub 2001 Oct 30.

15.

Linkage analysis of 150 high-risk prostate cancer families at 1q24-25.

Goode EL, Stanford JL, Chakrabarti L, Gibbs M, Kolb S, McIndoe RA, Buckley VA, Schuster EF, Neal CL, Miller EL, Brandzel S, Hood L, Ostrander EA, Jarvik GP.

Genet Epidemiol. 2000 Mar;18(3):251-75.

PMID:
10723109
16.

Long-term trends in susceptibility of Moraxella catarrhalis: a population analysis.

Walker ES, Neal CL, Laffan E, Kalbfleisch JH, Berk SL, Levy F.

J Antimicrob Chemother. 2000 Feb;45(2):175-82.

PMID:
10660499
17.
18.

Construction of a panel of canine-rodent hybrid cell lines for use in partitioning of the canine genome.

Langston AA, Mellersh CS, Neal CL, Ray K, Acland GM, Gibbs M, Aguirre GD, Fournier RE, Ostrander EA.

Genomics. 1997 Dec 15;46(3):317-25.

PMID:
9441734
19.

Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25.

McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL, Hood L, Ostrander EA.

Am J Hum Genet. 1997 Aug;61(2):347-53.

20.

Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.

Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA.

Cancer Res. 1997 Mar 15;57(6):1194-8.

21.

A class of highly polymorphic tetranucleotide repeats for canine genetic mapping.

Francisco LV, Langston AA, Mellersh CS, Neal CL, Ostrander EA.

Mamm Genome. 1996 May;7(5):359-62.

PMID:
8661717
22.

Dermoid cyst of the soft palate.

Green JD, Neal CL.

South Med J. 1982 Aug;75(8):1029. No abstract available.

PMID:
7112190
23.

An analysis of therapy for carcinoma of the tonsil.

Neal CL, Snow JB Jr, Seda HJ.

Trans Am Acad Ophthalmol Otolaryngol. 1973 Mar-Apr;77(2):ORL97-104. No abstract available.

PMID:
4729645

Supplemental Content

Support Center